Home » Newsletters » BioWorld Science

BioWorld Science

April 15, 2015

View Archived Issues

Bayer Schering Pharma discloses CCR2 antagonists

Vectus Biosystems patents novel compounds for hypertension and fibrosis

BIIB-037 shows promising results as a disease-modifying treatment in AD patients

4E-T identified as potential prognostic marker in breast carcinoma

JCR Pharma prepares for clinical development of sustained growth hormone formulation

PI3Kbeta inhibitors show promise for the treatment of PTEN-mutated tumors

Pharmacyclics patents BTK inhibitors

Daiichi Sankyo reports development of novel Nrf2 activators by biotransformation

Recro Pharma acquires injectable meloxicam for pain

Cipher Pharmaceuticals acquires dermatology company INNOCUTIS

Merck & Co. discloses novel HCV NS5A inhibitor

DiscoveryBioMed developing dual-action small-molecule monotherapy for cystic fibrosis

SBIR grant supports Xeris' development of stable non-aqueous glucagon for congenital hyperinsulinism

Lummy HK licenses Chinese rights to AGS-003 and Argos' Arcelis technology

Menarini licenses resminostat for development and marketing in Asia-Pacific excluding Japan

Astellas to collaborate with Ventana Medical Systems on companion diagnostic tests

Esperas Pharma launched to develop anticancer compound discovered at Lilly

Roche introduces mGlu4 receptor PAMs

Sunshine Lake Pharma patent describes SGLT2 inhibitors

Bayer Schering Pharma presents FXIa inhibitors

Columbia Laboratories changes name to Juniper Pharmaceuticals

Soligenix and FDA agree on protocol for phase III trial of SGX-203 for pediatric Crohn's disease

EMA approves compassionate use of OMS-721 in patients with aHUS

FDA grants orphan drug status to tremelimumab for malignant mesothelioma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...